Search research articles
Contact Us
Filters
Showing results (21-30 of 56) with videos related to
Page
of 6
Sort By:
Folia Endocrinologica
|
June 1, 1972
[Effects of pharmacological or surgical correction of hypercortisolism on incretion of S.T.H. in Cushing's syndrome]
P G Chiodini, A Liuzzi, F Spinelli-Ressi, et al.
Journal of Endocrinological Investigation
|
June 1, 1985
Medical treatment of pituitary adenomas: effects on tumor growth
A Liuzzi, P G Chiodini, D Dallabonzana, et al.
Neuroradiology
|
January 1, 1982
Macroprolactinomas: CT evaluation of reduction of tumor size after medical treatment
G Scotti, G Scialfa, S Pieralli, et al.
Journal of Endocrinological Investigation
|
April 1, 1985
Effect of chronic bromocriptine administration on tumor size in patients with "nonsecreting" pituitary adenomas
G Verde, G Oppizzi, P G Chiodini, et al.
Folia Endocrinologica
|
October 1, 1972
[Secretion dynamics of GH in 43 patients with acromegaly]
A Liuzzi, P G Chiodini, L Botalla, et al.
The Journal of Clinical Endocrinology and Metabolism
|
March 1, 1986
Bromocriptine does not alter growth hormone (GH) responsiveness to GH-releasing hormone in acromegaly
R Cozzi, D Dallabonzana, G Oppizzi, et al.
The Journal of Clinical Endocrinology and Metabolism
|
September 1, 1980
Homogeneity in the growth hormone-lowering effect of dopamine and somatostatin in acromegaly
G Oppizzi, L Botalla, G Verde, et al.
The Journal of Clinical Endocrinology and Metabolism
|
May 1, 1974
Decreased plasma growth hormone (GH) levels in acromegalics following CB 154(2-Br-alpha ergocryptine) administration
A Liuzzi, P G Chiodini, L Botalla, et al.
The Journal of Clinical Endocrinology and Metabolism
|
April 1, 1975
Stable reduction of plasma growth hormone (hGH) levels during chronic administration of 2-Br-alpha-ergocryptine (CB-154) in acromegalic patients
P G Chiodini, A Liuzzi, L Botalla, et al.
Journal of Endocrinological Investigation
|
April 1, 1985
Effect of the new ergot derivative terguride on plasma PRL and GH levels in patients with pathological hyperprolactinemia or acromegaly
D Dallabonzana, A Liuzzi, G Oppizzi, et al.
Page
of 6
Search research articles
Search
Showing results (21-30 of 56) with videos related to
Sort By:
Page
of 6
Folia Endocrinologica
|
June 1, 1972
[Effects of pharmacological or surgical correction of hypercortisolism on incretion of S.T.H. in Cushing's syndrome]
P G Chiodini, A Liuzzi, F Spinelli-Ressi, et al.
Journal of Endocrinological Investigation
|
June 1, 1985
Medical treatment of pituitary adenomas: effects on tumor growth
A Liuzzi, P G Chiodini, D Dallabonzana, et al.
Neuroradiology
|
January 1, 1982
Macroprolactinomas: CT evaluation of reduction of tumor size after medical treatment
G Scotti, G Scialfa, S Pieralli, et al.
Journal of Endocrinological Investigation
|
April 1, 1985
Effect of chronic bromocriptine administration on tumor size in patients with "nonsecreting" pituitary adenomas
G Verde, G Oppizzi, P G Chiodini, et al.
Folia Endocrinologica
|
October 1, 1972
[Secretion dynamics of GH in 43 patients with acromegaly]
A Liuzzi, P G Chiodini, L Botalla, et al.
The Journal of Clinical Endocrinology and Metabolism
|
March 1, 1986
Bromocriptine does not alter growth hormone (GH) responsiveness to GH-releasing hormone in acromegaly
R Cozzi, D Dallabonzana, G Oppizzi, et al.
The Journal of Clinical Endocrinology and Metabolism
|
September 1, 1980
Homogeneity in the growth hormone-lowering effect of dopamine and somatostatin in acromegaly
G Oppizzi, L Botalla, G Verde, et al.
The Journal of Clinical Endocrinology and Metabolism
|
May 1, 1974
Decreased plasma growth hormone (GH) levels in acromegalics following CB 154(2-Br-alpha ergocryptine) administration
A Liuzzi, P G Chiodini, L Botalla, et al.
The Journal of Clinical Endocrinology and Metabolism
|
April 1, 1975
Stable reduction of plasma growth hormone (hGH) levels during chronic administration of 2-Br-alpha-ergocryptine (CB-154) in acromegalic patients
P G Chiodini, A Liuzzi, L Botalla, et al.
Journal of Endocrinological Investigation
|
April 1, 1985
Effect of the new ergot derivative terguride on plasma PRL and GH levels in patients with pathological hyperprolactinemia or acromegaly
D Dallabonzana, A Liuzzi, G Oppizzi, et al.
Page
of 6